mandibuloacral dysplasia with type B lipodystrophy

disease
On this page

Also known as MADB

Summary

mandibuloacral dysplasia with type B lipodystrophy (MONDO:0012074) is a disease caused by ZMPSTE24 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: ZMPSTE24 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 61
  • Phenotypes (HPO): 28

Clinical features

Signs & symptoms

Clinical features (HPO)

28 HPO clinical features (Orphanet curated; top 28 by frequency):

HPO IDTermFrequency
HP:0000160Narrow mouthVery frequent (80-99%)
HP:0000239Large fontanellesVery frequent (80-99%)
HP:0000347MicrognathiaVery frequent (80-99%)
HP:0000924Abnormality of the skeletal systemVery frequent (80-99%)
HP:0000963Thin skinVery frequent (80-99%)
HP:0001870Acroosteolysis of distal phalanges (feet)Very frequent (80-99%)
HP:0002797OsteolysisVery frequent (80-99%)
HP:0004334Dermal atrophyVery frequent (80-99%)
HP:0006710Aplasia/Hypoplasia of the claviclesVery frequent (80-99%)
HP:0009839Osteolytic defects of the distal phalanges of the handVery frequent (80-99%)
HP:0009882Short distal phalanx of fingerVery frequent (80-99%)
HP:0000164Abnormality of the dentitionFrequent (30-79%)
HP:0000444Convex nasal ridgeFrequent (30-79%)
HP:0000520ProptosisFrequent (30-79%)
HP:0000855Insulin resistanceFrequent (30-79%)
HP:0000953Hyperpigmentation of the skinFrequent (30-79%)
HP:0001211Abnormal fingertip morphologyFrequent (30-79%)
HP:0001595Abnormality of the hairFrequent (30-79%)
HP:0001596AlopeciaFrequent (30-79%)
HP:0003077HyperlipidemiaFrequent (30-79%)
HP:0003196Short noseFrequent (30-79%)
HP:0003761CalcinosisFrequent (30-79%)
HP:0004322Short statureFrequent (30-79%)
HP:0005328Progeroid facial appearanceFrequent (30-79%)
HP:0007495Prematurely aged appearanceFrequent (30-79%)
HP:0008404Nail dystrophyFrequent (30-79%)
HP:0009064Generalized lipodystrophyFrequent (30-79%)
HP:0000823Delayed pubertyOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namemandibuloacral dysplasia with type B lipodystrophy
Mondo IDMONDO:0012074
MeSHC535706
OMIM608612
Orphanet90154
DOIDDOID:0081129
ICD-111199517264
UMLSC1837756
MedGen332940
GARD0009989
Is cancer (heuristic)no

Also known as: MADB · mandibuloacral dysplasia with type B lipodystrophy

Data availability: 61 ClinVar variants · 5 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › disorder of development or morphogenesisdevelopmental defect during embryogenesismultiple congenital anomalies/dysmorphic syndrome › multiple congenital anomalies/dysmorphic syndrome without intellectual disability › mandibuloacral dysplasiamandibuloacral dysplasia with type B lipodystrophy

Related subtypes (1): mandibuloacral dysplasia with type A lipodystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

61 retrieved; paginated sample, class counts are floors:

31 uncertain significance, 8 pathogenic, 6 conflicting classifications of pathogenicity, 6 benign, 4 likely benign, 3 benign/likely benign, 2 pathogenic/likely pathogenic, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
4274NM_005857.5(ZMPSTE24):c.121C>T (p.Gln41Ter)LOC129930253Pathogeniccriteria provided, single submitter
140532NM_005857.5(ZMPSTE24):c.627+1G>CZMPSTE24Pathogeniccriteria provided, multiple submitters, no conflicts
140536NM_005857.5(ZMPSTE24):c.691G>T (p.Glu231Ter)ZMPSTE24Pathogeniccriteria provided, single submitter
140537NM_005857.5(ZMPSTE24):c.709G>T (p.Glu237Ter)ZMPSTE24Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2441655NM_005857.5(ZMPSTE24):c.1133_1137del (p.Gly377_Phe378insTer)ZMPSTE24Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
30586NM_005857.5(ZMPSTE24):c.1349G>A (p.Trp450Ter)ZMPSTE24Pathogenicno assertion criteria provided
3382731NM_005857.5(ZMPSTE24):c.469C>T (p.Gln157Ter)ZMPSTE24Pathogeniccriteria provided, single submitter
4271NM_005857.5(ZMPSTE24):c.1085dup (p.Leu362fs)ZMPSTE24Pathogeniccriteria provided, multiple submitters, no conflicts
4272NM_005857.5(ZMPSTE24):c.1018T>C (p.Trp340Arg)ZMPSTE24Pathogenicno assertion criteria provided
4275NM_005857.5(ZMPSTE24):c.743C>T (p.Pro248Leu)ZMPSTE24Pathogeniccriteria provided, single submitter
3382730NM_005857.5(ZMPSTE24):c.1259_1270dup (p.Lys423_Lys424insThrPheAlaLys)ZMPSTE24Likely pathogeniccriteria provided, single submitter
130790NM_005857.5(ZMPSTE24):c.325T>G (p.Cys109Gly)ZMPSTE24Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
140518NM_005857.5(ZMPSTE24):c.1312C>T (p.Leu438Phe)ZMPSTE24Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
297262NM_005857.5(ZMPSTE24):c.770-14T>CZMPSTE24Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
297263NM_005857.5(ZMPSTE24):c.951_954+2delZMPSTE24Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
297265NM_005857.5(ZMPSTE24):c.1106G>A (p.Arg369Gln)ZMPSTE24Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
725823NM_005857.5(ZMPSTE24):c.1165T>C (p.Leu389=)ZMPSTE24Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
297258NM_005857.5(ZMPSTE24):c.-13G>ALOC129930253Uncertain significancecriteria provided, single submitter
297259NM_005857.5(ZMPSTE24):c.30G>T (p.Leu10Phe)LOC129930253Uncertain significancecriteria provided, multiple submitters, no conflicts
3892921NM_005857.5(ZMPSTE24):c.113C>T (p.Ala38Val)LOC129930253Uncertain significancecriteria provided, single submitter
875987NM_005857.5(ZMPSTE24):c.52C>T (p.Arg18Cys)LOC129930253Uncertain significancecriteria provided, single submitter
1386345NM_005857.5(ZMPSTE24):c.1416G>T (p.Met472Ile)ZMPSTE24Uncertain significancecriteria provided, multiple submitters, no conflicts
1514530NM_005857.5(ZMPSTE24):c.260C>T (p.Thr87Ile)ZMPSTE24Uncertain significancecriteria provided, multiple submitters, no conflicts
1905058NM_005857.5(ZMPSTE24):c.997C>A (p.Leu333Ile)ZMPSTE24Uncertain significancecriteria provided, multiple submitters, no conflicts
297261NM_005857.5(ZMPSTE24):c.555A>G (p.Leu185=)ZMPSTE24Uncertain significancecriteria provided, single submitter
297264NM_005857.5(ZMPSTE24):c.1050T>C (p.Ile350=)ZMPSTE24Uncertain significancecriteria provided, single submitter
297268NM_005857.5(ZMPSTE24):c.*212G>TZMPSTE24Uncertain significancecriteria provided, single submitter
297269NM_005857.5(ZMPSTE24):c.*296T>CZMPSTE24Uncertain significancecriteria provided, single submitter
297271NM_005857.5(ZMPSTE24):c.*536C>TZMPSTE24Uncertain significancecriteria provided, single submitter
297273NM_005857.5(ZMPSTE24):c.*696A>GZMPSTE24Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 11 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
ZMPSTE24StrongAutosomal recessivemandibuloacral dysplasia with type B lipodystrophy11

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
ZMPSTE24Orphanet:1662Restrictive dermopathy
ZMPSTE24Orphanet:740Hutchinson-Gilford progeria syndrome
ZMPSTE24Orphanet:90154Mandibuloacral dysplasia with type B lipodystrophy

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
ZMPSTE24HGNC:12877ENSG00000084073O75844CAAX prenyl protease 1 homologgencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
ZMPSTE24CAAX prenyl protease 1 homologTransmembrane metalloprotease whose catalytic activity is critical for processing lamin A/LMNA on the inner nuclear membrane and clearing clogged translocons on the endoplasmic reticulum.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Protease136.6×0.027

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
ZMPSTE24Proteaseyes3.4.24.84Peptidase_M48, CAXX_Prtase_1, Peptidase_M48_N

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
choroid plexus epithelium1
hair follicle1
nephron tubule1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
ZMPSTE24295ubiquitousmarkerhair follicle, choroid plexus epithelium, nephron tubule

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
ZMPSTE242,685

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
ZMPSTE24O758444

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
regulation of stress-activated protein kinase signaling cascade116852.0×7e-04ZMPSTE24
regulation of mitotic cell cycle DNA replication116852.0×7e-04ZMPSTE24
regulation of termination of RNA polymerase I transcription116852.0×7e-04ZMPSTE24
inflammatory cell apoptotic process18426.0×7e-04ZMPSTE24
maintenance of rDNA18426.0×7e-04ZMPSTE24
response to DNA damage checkpoint signaling18426.0×7e-04ZMPSTE24
prenylated protein catabolic process15617.3×7e-04ZMPSTE24
regulation of fibroblast proliferation15617.3×7e-04ZMPSTE24
CAAX-box protein processing15617.3×7e-04ZMPSTE24
negative regulation of miRNA processing15617.3×7e-04ZMPSTE24
calcium ion import into sarcoplasmic reticulum15617.3×7e-04ZMPSTE24
regulation of hormone metabolic process13370.4×0.001ZMPSTE24
CAMKK-AMPK signaling cascade12808.7×0.001ZMPSTE24
cardiac ventricle development12407.4×0.001ZMPSTE24
ventricular cardiac muscle tissue development12106.5×0.001ZMPSTE24
growth plate cartilage development12106.5×0.001ZMPSTE24
regulation of DNA damage response, signal transduction by p53 class mediator12106.5×0.001ZMPSTE24
regulation of defense response to virus12106.5×0.001ZMPSTE24
kidney morphogenesis11872.4×0.001ZMPSTE24
cardiac conduction11685.2×0.001ZMPSTE24
regulation of cellular senescence11404.3×0.002ZMPSTE24
positive regulation of gene expression via chromosomal CpG island demethylation11203.7×0.002ZMPSTE24
nuclear envelope organization1991.3×0.002ZMPSTE24
regulation of TOR signaling1936.2×0.002ZMPSTE24
regulation of ventricular cardiac muscle cell membrane repolarization1842.6×0.002ZMPSTE24
regulation of bone mineralization1732.7×0.002ZMPSTE24
regulation of multicellular organism growth1648.1×0.003ZMPSTE24
cardiac muscle cell development1624.1×0.003ZMPSTE24
cellular response to gamma radiation1601.9×0.003ZMPSTE24
regulation of glucose metabolic process1561.7×0.003ZMPSTE24

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
ZMPSTE2400

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
ZMPSTE247Binding:7

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
ZMPSTE243.4.24.84Ste24 endopeptidase

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug1ZMPSTE24
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
ZMPSTE247

Clinical trials & evidence

Clinical trials

Clinical trials: 0.